Catalyst Biosciences, Inc. has entered into a second amendment to the Business Combination Agreement, extending the Outside Date to October 30, 2023. They have also filed a Certificate of Elimination to eliminate matters related to their Series Y Preferred Stock. Catalyst held a special meeting of stockholders to approve various proposals, including the issuance of shares, conversion of preferred stock, and amendments to the certificate of incorporation. The completion of the transactions is subject to regulatory approvals, including approval from the China Securities Regulatory Commission (CSRC).